Cargando…

Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk

The pox-protein regimen tested in the RV144 trial is the only vaccine strategy demonstrated to prevent HIV-1 infection. Subsequent analyses identified antibody and cellular immune responses as correlates of risk (CoRs) for HIV infection. Early predictors of these CoRs could provide insight into vacc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andersen-Nissen, Erica, Fiore-Gartland, Andrew, Ballweber Fleming, Lamar, Carpp, Lindsay N., Naidoo, Anneta F., Harper, Michael S., Voillet, Valentin, Grunenberg, Nicole, Laher, Fatima, Innes, Craig, Bekker, Linda-Gail, Kublin, James G., Huang, Ying, Ferrari, Guido, Tomaras, Georgia D., Gray, Glenda, Gilbert, Peter B., McElrath, M. Juliana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7959397/ https://www.ncbi.nlm.nih.gov/pubmed/33720973 http://dx.doi.org/10.1371/journal.ppat.1009363

Ejemplares similares

Benign ethnic neutropenia in a South African population, and its association with HIV acquisition and adverse event reporting in an HIV vaccine clinical trial
por: Mpofu, Rephaim, et al.
Publicado: (2021)

Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials
por: Moodie, Zoe, et al.
Publicado: (2020)

Human gut microbiota is associated with HIV-reactive immunoglobulin at baseline and following HIV vaccination
por: Cram, Jacob A., et al.
Publicado: (2019)

HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens
por: Shen, Xiaoying, et al.
Publicado: (2020)

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial
por: Bekker, Linda-Gail, et al.
Publicado: (2018)

Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines
por: Laher, Fatima, et al.
Publicado: (2020)

HIV-1 Specific IgA Detected in Vaginal Secretions of HIV Uninfected Women Participating in a Microbicide Trial in Southern Africa Are Primarily Directed Toward gp120 and gp140 Specificities
por: Seaton, Kelly E., et al.
Publicado: (2014)

Multi-trial analysis of HIV-1 envelope gp41-reactive antibodies among global recipients of candidate HIV-1 vaccines
por: Mayer-Blackwell, Koshlan, et al.
Publicado: (2022)

Vaccine-Induced Antibodies Mediate Higher Antibody-Dependent Cellular Cytotoxicity After Interleukin-15 Pretreatment of Natural Killer Effector Cells
por: Fisher, Leigh, et al.
Publicado: (2019)

Predictors of HVTN 503 MRK-AD5 HIV-1 gag/pol/nef Vaccine Induced Immune Responses
por: Hopkins, Kathryn L., et al.
Publicado: (2014)

Initial Events in Establishing Vaginal Entry and Infection by Human Immunodeficiency Virus Type-1
por: Hladik, Florian, et al.
Publicado: (2007)

Review of preventative HIV vaccine clinical trials in South Africa
por: Laher, Fatima, et al.
Publicado: (2020)

Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein
por: Hosseinipour, Mina C, et al.
Publicado: (2020)

Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men
por: Moodie, Zoe, et al.
Publicado: (2015)

Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans
por: Zhao, Lue Ping, et al.
Publicado: (2020)

Uptake of Genital Mucosal Sampling in HVTN 097, a Phase 1b HIV Vaccine Trial in South Africa
por: Lazarus, Erica Maxine, et al.
Publicado: (2014)

A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa
por: Bekker, Linda-Gail, et al.
Publicado: (2020)

Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens
por: Huang, Yunda, et al.
Publicado: (2022)

Risk Factors Associated with HIV Acquisition in Males Participating in HIV Vaccine Efficacy Trials in South Africa
por: Malahleha, Mookho, et al.
Publicado: (2023)

Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults
por: Buchbinder, Susan P., et al.
Publicado: (2017)

Attracting, equipping and retaining young medical doctors in HIV vaccine science in South Africa
por: Flood, Danna, et al.
Publicado: (2015)

Real-time polymerase chain reaction optimised for hepatitis C virus detection in dried blood spots from HIV-exposed infants, KwaZulu-Natal, South Africa
por: Naidoo, Anneta, et al.
Publicado: (2016)

Hope for HIV control in southern Africa: The continued quest for a vaccine
por: Bekker, Linda-Gail, et al.
Publicado: (2017)

Safety and Immunogenicity of a Replication-Defective Adenovirus Type 5 HIV Vaccine in Ad5-Seronegative Persons: A Randomized Clinical Trial (HVTN 054)
por: Peiperl, Laurence, et al.
Publicado: (2010)

Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection
por: Ditse, Zanele, et al.
Publicado: (2020)

Vaginal practices among women at risk for HIV acquisition in Soweto, South Africa
por: Lazarus, Erica, et al.
Publicado: (2019)

Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection
por: Astronomo, Rena D., et al.
Publicado: (2016)

Pre-Existing Adenovirus Immunity Modifies a Complex Mixed Th1 and Th2 Cytokine Response to an Ad5/HIV-1 Vaccine Candidate in Humans
por: Pine, Samuel O., et al.
Publicado: (2011)

Meta-analysis of HIV-1 vaccine elicited mucosal antibodies in humans
por: Seaton, Kelly E., et al.
Publicado: (2021)

A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204)
por: Churchyard, Gavin J., et al.
Publicado: (2011)

Cross-protocol assessment of induction and durability of VISP/R in HIV preventive vaccine trial participants
por: Espy, Nicole, et al.
Publicado: (2023)

Impact of adjuvants on the biophysical and functional characteristics of HIV vaccine-elicited antibodies in humans
por: Xu, Shiwei, et al.
Publicado: (2022)

COVID-19 vaccination and HIV-1 acquisition – Authors’ reply
por: Buchbinder, Susan P, et al.
Publicado: (2022)

Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study
por: Baden, Lindsey R, et al.
Publicado: (2020)

Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants
por: Churchyard, Gavin, et al.
Publicado: (2016)

Pooled-Peptide Epitope Mapping Strategies Are Efficient and Highly Sensitive: An Evaluation of Methods for Identifying Human T Cell Epitope Specificities in Large-Scale HIV Vaccine Efficacy Trials
por: Fiore-Gartland, Andrew, et al.
Publicado: (2016)

Characterization of a vaccine-elicited human antibody with sequence homology to VRC01-class antibodies that binds the C1C2 gp120 domain
por: Gray, Matthew D., et al.
Publicado: (2022)

Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection
por: Ferrari, Guido, et al.
Publicado: (2017)

P17-25. A model for coverage of T-cell HIV vaccines: where are we and where do we need to be?
por: Self, S, et al.
Publicado: (2009)

HIV-1 Induces Cytotoxic T Lymphocytes in the Cervix of Infected Women
por: Musey, Luwy, et al.
Publicado: (1997)

Cannot write session to /tmp/vufind_sessions/sess_6aojlaooooji8739an8qe59u40